Macleod Pharmaceuticals- Next Multibagger IPO In Pharma Sector coming soon.
Mr Agarwal in 1985 incorporated a dream to make antiTB medicine is now planning for abig venture.
With knowledge of the statement told UG4Bulls. Mumbai based Drug maker Macleod Pharmaceuticals is also planning a domestic listing after Gland's, India’s biggest pharma IPO, mainly the second biggest ever in industry sources
“Macleod Pharma is in initial discussions with some investment bankers to evaluate the launch of an IPO in FY 22,” said one of the individuals cited above.
Company’s focus on healthcare and wellness in the capital markets in 2021 with as many as more than 30 IPOs across varied sectors raising around Rs 42,000 crores as of July 21, according to data from Prime Database.
By August The firm may look to raise at least Rs 3,500 crores via the listing though no final news has been taken on the scope,” a second individual told UG4Bulls.
“Firm is one of the larger unpublished unlisted pharmacy players and also have enough cash and are considering an IPO seeing the current flexibility in the market and the promising assessments for the pharmacy and healthcare segment,” steeply combined global firm that focusses in the expansion and production of finished dosage and active pharmaceutical ingredients.
UG4Bulls is expecting an written response from Macleod Pharma and after that this article will get updated as early.
As of July 2021, companies stock price has seen a remarkable flow of more than 150 percent since it listed on the domestic market on November 20, 2020.
21 more IPO’s, which have received Sebi approval or still have a valid approval are expected to hit the markets in the days ahead, in the process raising a combined sum of Rs 28,600 crores according to data from a source.
Macleod Pharma is one of the top 10 pharma companies in the country with growing sales, high profitability, strong distribution network and a presence in therapeutic areas.
Macleod’s Pharmaceuticals has 2 manufacturing facilities for APIs and 14 manufacturing facilities for finished dosage formulations, in India. The firm has made a venture into regulated markets and has an international presence in 7 countries.
The firm manufactures close to 26 billion units of finished dosages per year. These include tablets, capsules, liquid orals, powders for oral suspension, pressurized metered dose inhalers (pMDI), single dose dry powder inhalers (DPI), dry powders for injections (antiseptic fill) and a variety of topicals like lotions as per research of UG4BULLS.
It’s flagship division include almost 120 products reaches out to more than 2,00,000 doctors in India and caters to almost every specialty, with emphasis on pediatrics, consulting physicians, general practitioners, surgeons, dermatologists and gynecologists, according to its website.